Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting – Nasdaq
|
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Nasdaq CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, … |
